Mirco Di Marco
Overview
Explore the profile of Mirco Di Marco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
97
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mahale S, Setia M, Prajapati B, Subhash S, Yadav M, Thankaswamy Kosalai S, et al.
Nat Commun
. 2022 Aug;
13(1):4865.
PMID: 36038571
Although antisense transcription is a widespread event in the mammalian genome, double-stranded RNA (dsRNA) formation between sense and antisense transcripts is very rare and mechanisms that control dsRNA remain unknown....
2.
Juvvuna P, Mondal T, Di Marco M, Thankaswamy Kosalai S, Kanduri M, Kanduri C
Neurooncol Adv
. 2021 May;
3(1):vdab056.
PMID: 34056606
Background: has been an attractive therapeutic target in neuroblastoma considering the widespread amplification of the locus in neuroblastoma, and its established role in neuroblastoma development and progression. Thus, understanding neuroblastoma-specific...
3.
Ali M, Di Marco M, Mahale S, Jachimowicz D, Thankaswamy Kosalai S, Reischl S, et al.
Oncogene
. 2021 Mar;
40(13):2463-2478.
PMID: 33674747
Recent advances in genomics unraveled several actionable mutational drivers in lung cancer, leading to promising therapies such as tyrosine kinase inhibitors and immune checkpoint inhibitors. However, the tumors' acquired resistance...
4.
Di Marco M, Veschi S, Lanuti P, Ramassone A, Pacillo S, Pagotto S, et al.
Cancers (Basel)
. 2021 Jan;
13(2).
PMID: 33445508
The clinical progression of B cell chronic lymphocytic leukemia (CLL) is associated with immune cell dysfunction and a strong decrease of (), promoting the death of CLL cells. Here we...
5.
Mitra S, Muralidharan S, Di Marco M, Juvvuna P, Thankaswamy Kosalai S, Reischl S, et al.
Cancer Res
. 2020 Dec;
81(6):1457-1471.
PMID: 33372039
Neuroblastoma has a low mutation rate for the gene. Alternative ways of p53 inactivation have been proposed in neuroblastoma, such as abnormal cytoplasmic accumulation of wild-type p53. However, mechanisms leading...
6.
Di Marco M, De Novellis A, Carluccio V, Bozzelli R, Orlando M, Lanuti P
Environ Geochem Health
. 2019 Oct;
42(2):353-364.
PMID: 31630285
Medicinal mineral water, being provided by recognized immunosuppressive properties, results useful for treating many pathological conditions. A well-known source of sulfurous and oligomer medicinal mineral waters is located in Caramanico...
7.
Visone R, Bacalini M, Di Franco S, Ferracin M, Colorito M, Pagotto S, et al.
Epigenomics
. 2019 May;
11(6):587-604.
PMID: 31066579
To investigate the genome-wide methylation of genetically characterized colorectal cancer stem cell (CR-CSC) lines. Eight CR-CSC lines were isolated from primary colorectal cancer (CRC) tissues, cultured and characterized for aneuploidy,...
8.
Di Marco M, Ramassone A, Pagotto S, Anastasiadou E, Veronese A, Visone R
Int J Mol Sci
. 2018 Oct;
19(10).
PMID: 30322050
Autoimmunity and hematological malignancies are often concomitant in patients. A causal bidirectional relationship exists between them. Loss of immunological tolerance with inappropriate activation of the immune system, likely due to...
9.
Pagotto S, Veronese A, Soranno A, Lanuti P, Di Marco M, Russo M, et al.
Oncotarget
. 2018 Mar;
9(16):13036-13047.
PMID: 29560129
is overexpressed in most solid and hematological malignancies. It promotes loss of genomic integrity in cancer cells by targeting genes involved in microsatellite instability and DNA repair; however, the link...